<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T2" position="float">
 <label>Table 2</label>
 <caption>
  <title>Action of different substances against SARS-CoV-2 in vitro</title>
 </caption>
 <table frame="hsides" rules="all">
  <thead>
   <tr>
    <td valign="top" rowspan="1" colspan="1">
     <bold>Substance</bold>
    </td>
    <td valign="top" rowspan="1" colspan="1">
     <bold>Brief description</bold>
    </td>
    <td valign="top" rowspan="1" colspan="1">
     <bold>EC50 (ÂµM)</bold>
    </td>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top" rowspan="1" colspan="1">Remdesivir</td>
    <td valign="top" rowspan="1" colspan="1">Nucleotide analog (base with adenine-like structure) inhibits viral polymerase, developed as a substance to combat ebolaviruses, several clinical trials in COVID-19</td>
    <td valign="top" align="center" rowspan="1" colspan="1">0.77</td>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1">Chloroquine</td>
    <td valign="top" rowspan="1" colspan="1">4-Aminoquinoline derivative; prevention and treatment of malaria, also in rheumatoid arthritis; antiviral action due to elevated pH in endosomes (similar activity is known for hydroxychloroquine)</td>
    <td valign="top" align="center" rowspan="1" colspan="1">1.1</td>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1">Nitazoxanide</td>
    <td valign="top" rowspan="1" colspan="1">Nitrothiazole derivative, deacetylated in vivo to tizoxanide, acts against protozoa such as 
     <italic>Cryptosporidium parvum</italic> and some species of bacteria; additional antiviral action, clinical trials in influenza and other virus infections
    </td>
    <td valign="top" align="center" rowspan="1" colspan="1">2.1</td>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1">Nafamostat</td>
    <td valign="top" rowspan="1" colspan="1">Serine protease inhibitor, anticoagulant, inhibits membrane fusion, showed action against MERS-CoV in vitro</td>
    <td valign="top" align="center" rowspan="1" colspan="1">22</td>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1">Favipiravir</td>
    <td valign="top" rowspan="1" colspan="1">Pyrazine carboxamide, inhibits viral RNA-dependent RNA polymerase, licensed for treatment of influenza in Japan</td>
    <td valign="top" align="center" rowspan="1" colspan="1">62</td>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1">Penciclovir</td>
    <td valign="top" rowspan="1" colspan="1">Nucleoside analog, guanosine derivative, inhibits viral DNA polymerase; its prodrug famciclovir is licensed for treatment of herpes zoster</td>
    <td valign="top" align="center" rowspan="1" colspan="1">96</td>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1">Ribavirin</td>
    <td valign="top" rowspan="1" colspan="1">Nucleoside analog, guanosine derivative, inhibits inosine monophosphate dehydrogenase and inhibits DNA and RNA viruses; also has an immunomodulatory action; licensed for treatment of chronic hepatitis C</td>
    <td valign="top" align="center" rowspan="1" colspan="1">109</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>EC50 = Concentration with half-maximal effect</p>
  <p>(modified from Wang et al., 2020 [6])</p>
 </table-wrap-foot>
</table-wrap>
